Two single-center , four-way , single-dose , crossover studies assessed the systemic exposure , systemic pharmacodynamics ( PD ) , and safety profile of the closed triple fluticasone furoate / umeclidinium/vilanterol ( FF/UMEC/VI ) therapy compared with dual therapies .